|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Method | Datasets | Data Split | Preprocessing | Evaluation & Results |
| MDF-SA-DDI (2022) | - DrugBank v5.1.8- TWOSIDES v1.0 | - 80% train- 10% validation- 10% test | - ECFP4 molecular fingerprints- UniProt protein sequences | - 5-fold cross-validation- F1 score: 0.888 |
| MATT-DDI (2023) | - DrugBank v5.1.8- STRING v11.5- FAERS (2021Q1-2023Q1) | - Temporal split:- 70% pre-2022- 30% post-2022 | - MedDRA term mapping- ≥10 co-occurrences filter | - AUPR: 0.974- Held-out test evaluation |
| SubGE-DDI (2024) | - PubMed- DrugBank- DeepDDI benchmarks | - 90% train- 10% test | - Drug/AE entity recognition- Subgraph extraction | - 5-fold cross-validation- F1 score: 0.847 |
| MFSynDCP (2024) | - NCI-ALMANAC- CCLE | - Cell-line splits:- 80% train- 20% test | - Z-score normalized expression- RDKit drug features | - AUROC: 0.930- Synergy prediction |